ADVERTISEMENT



Google       

Home -> Law Blog Directory -> Intellectual Property Law Blogs -> The Trade Secrets Vault

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Intellectual Property Law

: The Trade Secrets Vault

I-Flow Corporation Continues to Enforce Its Patent and Trade Secret Rights against Apex Medical's Solace(R) Pump Distributed by Zone Medical, LLC

ADVERTISEMENTS
LAKE FOREST, Calif., Oct 10, 2008 (BUSINESS WIRE) -- I-Flow Corporation (IFLO: 7.09, +0.95, +15.5%) continues to enforce its patent and trade secret rights against Apex Medical Technologies, Inc. and its president, Mark McLaughlin, in the United States District Court for the Southern District of California. I-Flow is also enforcing its patent rights against distributors of Apex's Solace(R) Pump, including Zone Medical, LLC. In view of early successes achieved in the lawsuit in the Southern District of California, I-Flow will ask the Court to rule, as a legal matter, that Apex, McLaughlin and Zone have infringed the patent. I-Flow is also vigorously moving forward in the case to protect its valuable trade secrets. In response to the litigation brought by I-Flow, the defendants asked the United States Patent and Trademark Office to reexamine I-Flow's patent. The Patent Office routinely grants such requests and often times initially rejects previously issued patent claims. The Patent Office has taken this action after receiving Apex's position on the patent without input from I-Flow. I-Flow will now have an opportunity to present its position to the Patent Office in support of the patentability of the patent-in-suit, US Patent No. 5,284,481 ("the '481 patent"). I-Flow believes that, once its position has been presented to the Patent Office, the Patent Office will reconfirm the patent as it did in 1994 when it issued the '481 patent. Indeed, the primary prior art relied on by Apex, McLaughlin and Zone in the reexamination process that I-Flow has not yet participated in, and relied upon by the Patent Office in rejecting the claims, is in fact technology owned by I-Flow. "While we believe we have a strong case against Apex, it is important to note that our success is not built solely around one patent," said Donald M. Earhart, Chairman, President and CEO of I-Flow. "Our success is based on a total package that includes a high quality disposable pump, a patented silver-coated soaker catheter, more than 60 clinical studies, our FDA-cleared indications that ON-Q(R) significantly reduces the need for narcotics and provides better pain relief than narcotics alone following surgery and, last but not least, our unsurpassed surgical sales force that spans the U.S. No other company in the market today even comes close to matching the breadth of our quality product line and the strength of our distribution. This is why we are the leader in this space." To continue reading click here

Full post as published by The Trade Secrets Vault on October 11, 2008 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Related Law Articles

Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0175 secs (new cache)